1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Yuhan Corporation
  6. Summary
    A000100   KR7000100008

YUHAN CORPORATION

(A000100)
  Report
End-of-day quote Korea Stock Exchange  -  2022-06-30
56000.00 KRW    0.00%
05/20Tranche Update on Yuhan Corporation's Equity Buyback Plan announced on February 16, 2022.
CI
05/16Yuhan Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
03/10Yuhan Corporation Reports Earnings Results for the Full Year Ended December 31, 2021
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Korea Stock Exchange
06/27/2022 06/28/2022 06/29/2022 06/30/2022 07/01/2022 Date
55300 56100 55700 56000 56000 Last
145310 102408 95785 118834 154088 Volume
-0.72% +1.45% -0.71% +0.54% 0.00% Change
Estimated financial data (e)
Sales 2022 1 838 B 1,41 B 1,41 B
Net income 2022 110 B 0,08 B 0,08 B
Net cash position 2022 289 B 0,22 B 0,22 B
P/E ratio 2022 36,7x
Yield 2022 0,69%
Sales 2023 2 045 B 1,57 B 1,57 B
Net income 2023 146 B 0,11 B 0,11 B
Net cash position 2023 307 B 0,24 B 0,24 B
P/E ratio 2023 27,6x
Yield 2023 0,69%
Capitalization 3 810 B 2 930 M 2 930 M
EV / Sales 2022 1,92x
EV / Sales 2023 1,71x
Nbr of Employees 1 845
Free-Float 67,3%
More Financials
Company
Yuhan Corporation is a Korea-based company mainly engaged in the manufacture and sale of pharmaceuticals. Along with its subsidiaries, the Company operates its business through three segments. The Pharmaceutical segment is engaged in the production and sale of non-prescription drugs including anti-inflammatory drugs, as well as prescription drugs such as drugs for hepatitis, diabetes, and hypertension. The Life and... 
Sector
Pharmaceuticals
Calendar
07/29Earnings Release
More about the company
Ratings of Yuhan Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about YUHAN CORPORATION
05/20Tranche Update on Yuhan Corporation's Equity Buyback Plan announced on February 16, 202..
CI
05/16Yuhan Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
03/10Yuhan Corporation Reports Earnings Results for the Full Year Ended December 31, 2021
CI
02/16Yuhan Corporation announces an Equity Buyback for KRW 20,000 million worth of its share..
CI
02/16Yuhan Corporation authorizes a Buyback Plan.
CI
01/17ImmuneOncia Therapeutics Inc. announced that it has received KRW 24.5 billion in fundin..
CI
2021Yuhan Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended ..
CI
2021Yuhan Corporation announces an Equity Buyback for KRW 15,000,000 million worth of its s..
CI
2021Yuhan Corporation's Equity Buyback Plan Extended till July 31, 2022.
CI
2021Yuhan Corporation authorizes a Buyback Plan.
CI
2021Yuhan Corporation's Equity Buyback Plan Extended till July 31, 2022.
CI
2021Yuhan Corporation's Equity Buyback Plan Extended till July 31, 2022.
CI
2021Yuhan Corporation's Equity Buyback Plan Extended till July 31, 2022.
CI
2021Yuhan Corporation's Equity Buyback Plan Extended till July 31, 2022.
CI
2021Yuhan Corporation's Equity Buyback Plan Extended till July 31, 2022.
CI
More news
News in other languages on YUHAN CORPORATION
05/16Yuhan Corporation publie ses résultats financiers pour le premier trimestre clos le 31 ..
03/10Yuhan Corporation annonce ses résultats financiers pour l'année complète se terminant l..
02/16YUHAN CORPORATION (KOSE : A000100) annonce un rachat d'actions pour une valeur de KRW 20.0..
02/16La société Yuhan autorise un plan de rachat.
2021DISCUSSIONS SUR LE MARCHÉ : La coentreprise Yuhan-Kimberly-Clark s'associe à un partenaria..
More news
Chart YUHAN CORPORATION
Duration : Period :
Yuhan Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends YUHAN CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 17
Last Close Price 56 000,00 KRW
Average target price 78 723,81 KRW
Spread / Average Target 40,6%
EPS Revisions
Managers and Directors
Jeong-Hui Lee President, Chief Executive Officer & Director
Sang-Chul Kim Director, Head-Research & Development
Han Kon Kim Head-Global Operations
Jong-Soo Lee Head-Compliance Support
In-Young Go Independent Director
Sector and Competitors
1st jan.Capi. (M$)
YUHAN CORPORATION-9.82%2 930
MERCK KGAA-27.00%74 935
KYOWA KIRIN CO. LTD.-3.19%12 062
SK BIOPHARMACEUTICALS CO., LTD.-27.57%4 240
BETTA PHARMACEUTICALS CO., LTD.-30.24%3 452
INDIVIOR PLC18.52%2 559